![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Cougar Biotechnology (MM) | NASDAQ:CGRB | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 42.96 | 0 | 01:00:00 |
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of report (date of earliest event reported): May 31, 2009
Cougar
Biotechnology, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
(State
or other jurisdiction of incorporation)
001-33871 |
20-2903204 |
|
(Commission File Number) |
(IRS Employer Identification No.) |
10990 Wilshire Blvd, Suite 1200 Los Angeles, CA 90024 |
(Address of principal executive offices) (Zip Code) |
(310) 943-8040
(Registrant’s telephone number, including area
code)
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
⃞ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
⃞ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
⃞ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
⃞ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On May 31, 2009, Cougar Biotechnology, Inc. (the “Company”) issued a press release announcing results from ongoing clinical trials of the Company’s investigational drug CB7630 (abiraterone acetate), which data were presented at the 2009 Annual Meeting of the American Society of Clinical Oncology. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. | Description | |
99.1 | Press release dated May 31, 2009 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
COUGAR BIOTECHNOLOGY, INC. |
|||||
|
|||||
Date: |
June 1, 2009 |
By: |
/s/ Charles R. Eyler |
||
Charles R. Eyler |
|||||
Treasurer and Sr. Vice President, Finance |
INDEX TO EXHIBITS FILED WITH THIS REPORT
Exhibit No. | Description | |
99.1 | Press release dated May 31, 2009. |
1 Year Cougar Biotechnology (MM) Chart |
1 Month Cougar Biotechnology (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions